Is Acadia a good stock to buy now?
finds support from accumulated volume at $22.45 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This stock has average movements during the day and with good trading volume, the risk is considered to be medium.
Will Acadia Pharmaceuticals stock go up?
The 18 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 31.00, with a high estimate of 37.00 and a low estimate of 20.00. The median estimate represents a +64.89% increase from the last price of 18.80.
Is ACAD a good investment?
Why is ACAD stock down today?
Is Acadia a good company?
What does Acadia Pharmaceuticals make?
An unexpected regulatory setback is weighing on the biotech's shares
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
What happened
Shares of the mid-cap biopharma Acadia Pharmaceuticals ( NASDAQ:ACAD) fell by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is crashing today in response to a regulatory setback for pimavanserin's proposed label expansion as a treatment for dementia-related psychosis.
So what
Pimavanserin is currently approved as a treatment for hallucinations and delusions associated with Parkinson's disease psychosis under the brand name Nuplazid. Acadia has been trialing the drug for several years across a variety of broadly similar indications in the hope of expanding its commercial footprint.
Now what
Acadia noted in its press release that the FDA has yet to reach a final decision on pimavanserin's sNDA. But the company also revealed that the FDA has yet to share the specifics about the application's problematic areas.
How much did Acadia lose in 2020?
ACADIA reported fourth-quarter 2020 loss of 42 cents per share, narrower than the Zacks Consensus Estimate of a loss of 48 cents. However, the loss was wider than the year-ago quarter’s loss of 34 cents.
How much was R&D in the quarter?
Research and development (R&D) expenses were $62.1 million in the quarter, up 8% from the year-ago period due to higher expenses related to the acquisition of CerSci Therapeutics in August last year.
First-quarter performance
In the first quarter, Acadia Pharmaceuticals reported revenues of $62.96 million, a YoY rise of 28.83%. The revenues surpassed the consensus estimate by $2.03 million. The company reported non-GAAP EPS of -$0.59, a YoY decline of 34.09%. This is lower than the consensus estimate by $0.06.
Nuplazid in PD psychosis
In the first quarter, Nuplazid reported increasing uptake across both specialty pharmacy and specialty distribution channels. The company has also stopped selling the 17-mg tablet of the drug. Instead, the company is now marketing its 34-mg capsule.
Challenges
Nuplazid, however, has faced multiple challenges since its launch. In November 2017, the Institute for Safe Medication Practices released a report highlighting 244 deaths reported since its launch up to March 2017. On April 9, 2018, a CNN article further highlighted the safety events and fatalities associated with Nuplazid.
Nuplazid label expansion
The next major clinical trial readout for Acadia Pharmaceuticals should come out towards the end of fiscal 2019. Acadia is awaiting top-line results from the Phase 2 ADVANCE study, evaluating Nuplazid as adjunctive therapy in schizophrenic patients experiencing prominent negative symptoms. These patients are also on adequate antipsychotic therapy.
Is ACADIA Pharmaceuticals a buy right now?
18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACADIA Pharmaceuticals stock.
What stocks does MarketBeat like better than ACADIA Pharmaceuticals?
Wall Street analysts have given ACADIA Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ACADIA Pharmaceuticals wasn't one of them.
When is ACADIA Pharmaceuticals' next earnings date?
ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.#N#View our earnings forecast for ACADIA Pharmaceuticals.
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings data on Tuesday, August, 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.03.
How has ACADIA Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?
ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACAD shares have decreased by 56.4% and is now trading at $16.09.#N#View which stocks have been most impacted by COVID-19.
What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?
ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480 million-$515 million, compared to the consensus revenue estimate of $521.79 million.
What price target have analysts set for ACAD?
18 brokers have issued twelve-month price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $18.00 to $57.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $28.73 in the next twelve months.
Nuplazid's dementia-related psychosis data stole the show at a major scientific conference yesterday
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
What happened
Shares of mid-cap drugmaker Acadia Pharmaceuticals ( NASDAQ:ACAD) rose by as much as 13% in pre-market trading today.
So what
Earlier this year, Acadia announced that Harmony had been halted early because patients on placebo were more than twice as likely to show worsening symptoms compared to those on Nuplazid. This latest update provided additional information on the drug's all-important safety profile in this patient population.
Now what
In the accompanying press release, Acadia's management said that they plan to chat with the FDA about a possible regulatory pathway within the first half of next year. With such strong late-stage results and a clear-cut medical need, though, investors might be wondering why the company simply doesn't proceed with a regulatory filing.
